Rosita Zakeri1,2, Ann D Morgan3, Varun Sundaram3,4, Chloe Bloom3, John G F Cleland3,5, Jennifer K Quint3. 1. Department of Population Science and Gene Health, National Heart and Lung Institute, Imperial College London, London, UK. rosita.zakeri@kcl.ac.uk. 2. School of Cardiovascular Medicine & Sciences, King's College London British Heart Foundation Centre for Research Excellence, 125 Coldharbour Lane, London, SE5 9NU, UK. rosita.zakeri@kcl.ac.uk. 3. Department of Population Science and Gene Health, National Heart and Lung Institute, Imperial College London, London, UK. 4. Department of Cardiovascular Medicine, Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA. 5. Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow, Glasgow, UK.
Abstract
BACKGROUND: Patients with atrial fibrillation (AF) complicated by heart failure (HF) have a poor prognosis. We investigated whether long term loop-diuretic therapy in patients with AF and no known diagnosis of HF, as a potential surrogate marker of undiagnosed HF, is also associated with worse outcomes. METHODS: Adults with incident AF were identified from UK primary and secondary care records between 2004 and 2016. Repeat prescriptions for loop diuretics, without a diagnosis of HF or documented non-cardiac indication, were classified as 'isolated' loop diuretic use. RESULTS: Amongst 124,256 people with incident AF (median 76 years, 47% women), 22,001 (17.7%) had a diagnosis of HF, and 22,325 (18.0%) had isolated loop diuretic use. During 2.9 (LQ-UQ 1-6) years' follow-up, 12,182 patients were diagnosed with HF (incidence rate 3.2 [95% CI 3.1-3.3]/100 person-years). Of these, 3999 (32.8%) had prior isolated loop diuretic use, including 31% of patients diagnosed with HF following an emergency hospitalisation. The median time from AF to HF diagnosis was 3.6 (1.2-7.7) years in men versus 5.1 (1.8-9.9) years in women (p = 0.0001). In adjusted models, patients with isolated loop diuretic use had higher mortality (HR 1.42 [95% CI 1.37-1.47], p < 0.0005) and risk of HF hospitalisation (HR 1.60 [95% CI 1.42-1.80], p < 0.0005) than patients with no HF or loop diuretic use, and comparably poor survival to patients with diagnosed HF. CONCLUSIONS: Loop diuretics are commonly prescribed to patients with AF and may indicate increased cardiovascular risk. Targeted evaluation of these patients may allow earlier HF diagnosis, timely intervention, and better outcomes, particularly amongst women with AF, in whom HF appears to be under-recognised and diagnosed later than in men.
BACKGROUND:Patients with atrial fibrillation (AF) complicated by heart failure (HF) have a poor prognosis. We investigated whether long term loop-diuretic therapy in patients with AF and no known diagnosis of HF, as a potential surrogate marker of undiagnosed HF, is also associated with worse outcomes. METHODS: Adults with incident AF were identified from UK primary and secondary care records between 2004 and 2016. Repeat prescriptions for loop diuretics, without a diagnosis of HF or documented non-cardiac indication, were classified as 'isolated' loop diuretic use. RESULTS: Amongst 124,256 people with incident AF (median 76 years, 47% women), 22,001 (17.7%) had a diagnosis of HF, and 22,325 (18.0%) had isolated loop diuretic use. During 2.9 (LQ-UQ 1-6) years' follow-up, 12,182 patients were diagnosed with HF (incidence rate 3.2 [95% CI 3.1-3.3]/100 person-years). Of these, 3999 (32.8%) had prior isolated loop diuretic use, including 31% of patients diagnosed with HF following an emergency hospitalisation. The median time from AF to HF diagnosis was 3.6 (1.2-7.7) years in men versus 5.1 (1.8-9.9) years in women (p = 0.0001). In adjusted models, patients with isolated loop diuretic use had higher mortality (HR 1.42 [95% CI 1.37-1.47], p < 0.0005) and risk of HF hospitalisation (HR 1.60 [95% CI 1.42-1.80], p < 0.0005) than patients with no HF or loop diuretic use, and comparably poor survival to patients with diagnosed HF. CONCLUSIONS:Loop diuretics are commonly prescribed to patients with AF and may indicate increased cardiovascular risk. Targeted evaluation of these patients may allow earlier HF diagnosis, timely intervention, and better outcomes, particularly amongst women with AF, in whom HF appears to be under-recognised and diagnosed later than in men.
Authors: Michiel Rienstra; Steven A Lubitz; Saagar Mahida; Jared W Magnani; João D Fontes; Moritz F Sinner; Isabelle C Van Gelder; Patrick T Ellinor; Emelia J Benjamin Journal: Circulation Date: 2012-06-12 Impact factor: 29.690
Authors: Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis L Clement; Antonio Coca; Giovanni de Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre E Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland E Schmieder; Evgeny Shlyakhto; Costas Tsioufis; Victor Aboyans; Ileana Desormais Journal: Eur Heart J Date: 2018-09-01 Impact factor: 29.983
Authors: Cathrine W Knudsen; Paul Clopton; Arne Westheim; Tor Ole Klemsdal; Alan H B Wu; Philippe Duc; James McCord; Richard M Nowak; Judd E Hollander; Alan B Storrow; William T Abraham; Peter A McCullough; Alan S Maisel; Torbjørn Omland Journal: Ann Emerg Med Date: 2005-06 Impact factor: 5.721
Authors: Jonathan P Piccini; Bradley G Hammill; Moritz F Sinner; Adrian F Hernandez; Allan J Walkey; Emelia J Benjamin; Lesley H Curtis; Susan R Heckbert Journal: Eur Heart J Date: 2013-11-25 Impact factor: 29.983
Authors: Sander van Doorn; Geert-Jan Geersing; Rogier F Kievit; Yvonne van Mourik; Loes C Bertens; Evelien E S van Riet; Leandra J Boonman-de Winter; Karel G M Moons; Arno W Hoes; Frans H Rutten Journal: Heart Date: 2018-03-16 Impact factor: 5.994
Authors: Roy G P J de Jong; Arlene M Gallagher; Emily Herrett; Ad A M Masclee; Maryska L G Janssen-Heijnen; Frank de Vries Journal: Pharmacoepidemiol Drug Saf Date: 2016-07-27 Impact factor: 2.890